magrolimab Archives -

Gilead Sciences can restart pivotal trials of its cancer antibody magrolimab – the centrepiece of its $4.9 billion acquisition of

Gilead cleared to restart trials of CD47 drug magrolimab

https://pharmaphorum.com/news/gilead-cleared-to-restart-trials-of-cd47-drug-magrolimab/

The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences’ magrolimab, the centre piece

FDA slaps hold on trials of Gilead’s CD47 drug magrolimab

https://pharmaphorum.com/news/fda-slaps-hold-on-trials-of-gileads-cd47-drug-magrolimab/

Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the

Gilead trumpets data with newly-bought magrolimab in blood cancers

https://pharmaphorum.com/news/gilead-magrolimab-blood-cancer-asco/

magrolimab